-
-
-
-
-
-
-
BeiGene Reports Third Quarter 2022 Financial Results
-
-
-
-
-
-
-
BeiGene Reports Fourth Quarter and Full Year 2021 Financial Results
-
-
-
-
-
-
-
BeiGene Presents Results from Phase 3 Trial of Tislelizumab in Nasopharyngeal Cancer at ESMO Immuno-Oncology Congress 2021
-
-
-
-
-
-
-
BeiGene Announces U.S. FDA Acceptance and Priority Review of Supplemental New Drug Application for BRUKINSA® (Zanubrutinib) in Marginal Zone Lymphoma
-
-
-
12,344 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All